Erythropoietin stimulating agents and epoetin alfa revisited: what's really relevant?

Clin J Am Soc Nephrol. 2008 Jul;3(4):935-7. doi: 10.2215/CJN.02300508. Epub 2008 Jun 25.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Anemia / blood
  • Anemia / drug therapy*
  • Anemia / etiology
  • Chronic Disease
  • Drug Administration Schedule
  • Epoetin Alfa
  • Erythropoiesis / drug effects
  • Erythropoietin / administration & dosage*
  • Erythropoietin / adverse effects
  • Erythropoietin / blood*
  • Erythropoietin / pharmacokinetics
  • Hematinics / administration & dosage*
  • Hematinics / adverse effects
  • Hematinics / pharmacokinetics
  • Hematocrit
  • Hemoglobins / metabolism
  • Humans
  • Kidney Diseases / blood
  • Kidney Diseases / complications*
  • Kidney Diseases / drug therapy
  • Patient Selection
  • Recombinant Proteins
  • Treatment Outcome

Substances

  • Hematinics
  • Hemoglobins
  • Recombinant Proteins
  • Erythropoietin
  • Epoetin Alfa